Photocure $PHO.OL renewed breakout watch ahead of Q2 report
Investors are eagerly awaiting Photocures
PHO
Q2 2019 report to get a more indepth description of the recently announced Cevira partnership deal.
Also key is the information about the current growth rate on Cysview sales in US.
NOK 60-64 is a key level of expected resistance, as it is where the share price peaked in 2018, while a negative reaction could easily mean a pullback well below the NOK 50 level, which mean that an entry ahead of the upcoming Q2 presentation should be made with a keen eye on risk management.
Recent Edison Analysis after Cevira Deal announcement, BUY target price 70 NOK:
https://www.edisongroup.com/publication/a-licensing-deal-for-cevira/24556/
PHO
Q2 2019 report to get a more indepth description of the recently announced Cevira partnership deal. Also key is the information about the current growth rate on Cysview sales in US.
NOK 60-64 is a key level of expected resistance, as it is where the share price peaked in 2018, while a negative reaction could easily mean a pullback well below the NOK 50 level, which mean that an entry ahead of the upcoming Q2 presentation should be made with a keen eye on risk management.
Recent Edison Analysis after Cevira Deal announcement, BUY target price 70 NOK:
https://www.edisongroup.com/publication/a-licensing-deal-for-cevira/24556/
